Prognostic significance of survivin expression in diffuse large B-cell lymphomas

Blood

Volumn 96, Issue 5, 2000, Pages 1921-1925

  Adida, C ^a   Haioun, C ^a   Gaulard, P ^a   Lepage, E ^a   Morel, P ^a   Briere, J ^a   Dombret, H ^a   Reyes, F ^a   Diebold, J ^a   Gisselbrecht, C ^a   Salles, G ^a   Altieri, D C ^a   Molina, T J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SURVIVIN;

ADOLESCENT; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE-CELL, DIFFUSE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTEIN BIOSYNTHESIS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 0034284050     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project
2. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group
3. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report
4. Prognostic factors in aggressive malignant lymphomas: Description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs
5. A predictive model for aggressive non-Hodgkin's lymphoma. The international Non-Hodgkin's Lymphoma Prognostic Factors Project
6. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
7. Prognostic significance of bcl-2 protein expression in aggressive non- Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA)
8. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: A population-based study
9. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: A British National Lymphoma Investigation Study
10. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma
11. Correlation between mutation in p53, p53 expression, cyto-genetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma
12. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma
13. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
14. IAP family proteins-suppressors of apoptosis
15. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation
16. Analysis of human transcriptomes
17. Control of apoptosis and mitotic spindle checkpoint by survivin
18. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
19. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma
20. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer
21. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
22. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma
23. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
24. LNH-84 regimen: A multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma
25. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. Groupe d'Etude des Lymphomes de l'Adulte
26. Randomized comparison of ACVBP and m-BACOD for patients with low-risk aggressive lymphoma: The LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte
27. Alternance of chemotherapy does not improve results in aggressive non-Hodgkin's lymphoma: A prospective randomized study on 884 patients LNH 87 protocol group 3: A GELA study
28. Elderly patients with aggressive non-Hodgkin's lymphoma: Disease presentation, response to treatment, and survival - A Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years
29. Updated Kiel classification for lymphomas
30. Nonparametric estimation from incomplete observations
31. Regression models and life-tables
32. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer
33. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs
34. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas
35. The Bcl-2 protein family: Arbiters of cell survival
36. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line
37. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma